Previous 10 | Next 10 |
Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ chief financial officer, is scheduled to participate at the Cowen 42 nd Annual Health Care Conference on Wednesday, March 9, 2022 at 1:30 p.m. EST. A live webcast of the event will be available o...
Image source: The Motley Fool. Cerus (NASDAQ: CERS) Q4 2021 Earnings Call Feb 22, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Cerus (CERS) Q4 2021 Earnings Call Transcript
Cerus Corporation (CERS) Q4 2021 Results Conference Call February 22, 2022 04:30 PM ET Company Participants Matt Notarianni - Senior Director, IR Obi Greenman - President and CEO Kevin Green - CFO Carol Moore - SVP, Regulatory Affairs and Quality Jessica Hanover - VP, Corporate Affairs Confer...
Cerus press release (NASDAQ:CERS): Q4 GAAP EPS of -$0.05 beats by $0.03. Revenue of $39.87M (+41.4% Y/Y) in-line. The Company is reiterating its 2022 annual product revenue guidance range of $157 million to $164 million, representing a 20% to 25% increase over full-year 2021 reported product ...
Strong Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $50.1 Million Grew 49% in the Fourth Quarter Product Revenue of $39.9 Million Grew 41% in the Fourth Quarter Reiterating Full-Year 2022 Product Revenue Guidance Range of $157-...
Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during w...
Preliminary Q4:21 and Full-Year 2021 Product Revenues of $39.9 million and $130.9 million reflects year-over-year growth of 41% and 42%, respectively 2022 Product Revenues expected to be between $157-164 million, reflecting 20%-25% growth versus 2021 Expanding Access t...
Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...
Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ chief financial officer, is scheduled to participate in the Stephens Annual Investment Conference in Nashville, Tenn., on Friday, December 3, 2021 at 2:00 p.m. ET. A live webcast of the event will be...
Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Mo...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...